Alan Lau

Alan Lau is currently a Principal Scientist within Oncology R&D at AstraZeneca in Cambridge, UK, focusing on DNA damage response projects. In this role, they serve as the pre-clinical bioscience lead for ceralasertib, an ATR inhibitor in late-stage Phase II/III trials. Alan's extensive experience spans the drug discovery and development pipeline, including positions at KuDOS Pharmaceuticals, where they contributed to the discovery of the PARP inhibitor Lynparaza. They hold a PhD from the University of Leicester and have previously worked as a postdoctoral researcher at institutions such as the University of Leicester and the Wellcome Trust/Cancer Research UK Gurdon Institute.